CXCR4-targeted PET/CT in early systemic sclerosis–associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-08000-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Michael Gernert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Receptors, CXCR4, Scleroderma, Systemic, Lung Diseases, Interstitial. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Würzburg.
Abstract (Originalsprache)
Introduction
Distinguishing active inflammatory or remodeling-associated processes from irreversible fibrosis in systemic sclerosis remains challenging using conventional imaging modalities. The tracer [ 68 Ga]Pentixafor targets the C-X-C motif chemokine receptor 4 (CXCR4) which is expressed on leukocytes. Uptake of [ 68 Ga]Pentixafor may provide complementary biological information on CXCR4-associated inflammatory and remodeling activity.
Methods
This prospective cohort study included patients with early SSc (disease duration ≤ 5 years) and preexisting interstitial lung disease. All patients underwent [ 68 Ga]Pentixafor-PET/CT imaging. Normalized [ 68 Ga]Pentixafor uptake was quantified using the target-to-background ratio (TBR). Follow-up data on disease progression was collected. A control group comprised patients with giant cell arteritis.
Results
Twelve patients with SSc were included. The highest [ 68 Ga]Pentixafor uptake was observed in the hilar and mediastinal lymph nodes, in fibrotic lung regions, and in the left ventricular myocardium. In all three regions, a significantly higher [ 68 Ga]Pentixafor uptake was measured in SSc compared to controls (median TBR of lymph nodes 3.5 [IQR 2.7 – 4.3] vs 1.6 [1.3 – 2.0] p < 0.0001; inferior lung lobes 2.3 [1.6 – 2.8] vs 0.8 [0.7 – 1.0], p < 0.0001; and left ventricle 2.0 [1.4 – 2.4] vs 1.3 [1.1 – 1.5], p = 0.0178). Patients who developed progressive lung disease during follow-up showed a higher [ 68 Ga]Pentixafor uptake compared to non-progressive patients reaching statistical significance in the left ventricle (TBR of progressive vs non-progressive patients: 2.5 (2.1 – 3.3) vs 1.5 (1.3 – 2.1), p = 0.0283) and showing a numerical increase in fibrotic lung regions (2.8 (2.2 – 3.3) vs 1.7 (1.1 – 2.8), p = 0.1535).
Conclusion
These findings provide proof-of-concept evidence that CXCR4-targeted PET/CT may visualize biologically active inflammatory and/or remodeling processes in early-stage SSc-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany.
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Würzburg, Würzburg, Germany.
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
- The Russell H Morgan, Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany. serfling_s1@ukw.de.
ORCID-Profile: Sebastian E Serfling
Förderung
- Universitätsklinikum Würzburg
Zitieren
APA
Gernert, M., Schmalzing, M., Labinsky, H., Zhi, Y., Strunz, P. P., Fröhlich, M., Hartrampf, P. E., Buck, A. K., Werner, R. A., & Serfling, S. E. (2026). CXCR4-targeted PET/CT in early systemic sclerosis–associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08000-3
Vancouver
Gernert M, Schmalzing M, Labinsky H, Zhi Y, Strunz PP, Fröhlich M, et al. CXCR4-targeted PET/CT in early systemic sclerosis–associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08000-3
BibTeX
@article{Gernert2026,
author = {Gernert, Michael and Schmalzing, Marc and Labinsky, Hannah and Zhi, Yingjun and Strunz, Patrick-Pascal and Fröhlich, Matthias and Hartrampf, Philipp E and Buck, Andreas K and Werner, Rudolf A and Serfling, Sebastian E},
title = {CXCR4-targeted PET/CT in early systemic sclerosis–associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-08000-3}
}
EUVIMED